Livzon Pharmaceutical Group Inc (1513)

Currency in HKD
37.00
-0.28(-0.75%)
Closed·

1513 Financial Summary

Key Ratios

P/E Ratio17.43
Price/Book2.18
Debt / Equity25.09%
Return on Equity15.53%
Dividend Yield3.24%
EBITDA3.09B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2018
01/01
2018
31/12
2020
01/01
2021
01/01
2022
01/01
2022
31/12
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.29%
Dividend Yield
3.24%
Industry Median 2.41%
Annualised payout
1.20
Paid annually
5-Years Growth
-0.89%
Growth Streak

Analyst Ratings

3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 34.97
(-5.49% Downside)

Earnings

Latest Release
Apr 23, 2025
EPS / Forecast
0.71 / 0.68
Revenue / Forecast
3.18B / 3.34B
EPS Revisions
Last 90 days

FAQ

What were Livzon Pharma's earnings for the latest quarter?

The Livzon Pharma EPS (TTM) is 2.29. Livzon Pharma reported sales of 3,180.55, net income of 636.71, and EPS of 0.71 for the latest quarter.

What was Livzon Pharma's net income for the latest quarter?

Livzon Pharma's net income for the latest quarter was 636.71.

How did Livzon Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 2,730.74 in the previous quarter to 3,180.55 in the latest quarter, and net income moved from 388.36 to 636.71 compared to the previous quarter.

What is Livzon Pharma's net profit margin on a TTM basis?

Livzon Pharma's trailing twelve months (TTM) net profit margin is 17.45%.

How does Livzon Pharma's debt to equity ratio compare to industry standards?

Livzon Pharma's total debt-to-equity ratio is 25.09%.

What is Livzon Pharma's return on investment on a TTM basis?

Livzon Pharma's trailing twelve months (TTM) return on investment (ROI) is 15.53%.

Did Livzon Pharma gain or lose cash last quarter?

In the latest quarter, Livzon Pharma's net change in cash was 3.63 million.

What were Livzon Pharma's total assets and liabilities in the latest quarter?

As of the latest quarter, Livzon Pharma reported total assets of 24,485.27 million and total liabilities of 7,235.30 million.

How has Livzon Pharma's total revenue grown this year?

Livzon Pharma's total revenue was 2,730.74 in the previous quarter and 3,180.55 in the latest quarter.

What is Livzon Pharma's gross margin on a TTM basis?

Livzon Pharma's trailing twelve months (TTM) gross margin is 64.11%.

What was Livzon Pharma's revenue per share for the latest quarter?

Livzon Pharma's revenue per share for the latest quarter was 5.23.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.